Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $51.22 +0.02 (0.04%) 5:24 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Price, Consensus and EPS Surprise
SNY 51.20 +0.77(1.53%)
Will SNY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SNY
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
Other News for SNY
Sanofi call volume above normal and directionally bullish
Sanofi’s Dupixent: A New Era in COPD Treatment
Merck RSV therapy succeeds in infants in challenge to Sanofi, Astra
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife